glp 1 agonist parkinson Are we measuring the wrong primary outcome for GLP-1 drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Glucagon-like peptide-1 (GLP-1) receptor agonists

The clinical data reflects this: a 2022 retrospective analysis of 340 patients receiving lipotropic injections as part of a medically-supervised weight loss program found that those who maintained a 500-calorie daily deficit lost an average of 8.4% body weight over 16 weeks, compared to 5.1% in matched controls on caloric restriction alone

By activating all three receptors, Retatrutide helps increase insulin secretion, suppress glucagon, improve fat metabolism, reduce appetite, and enhance overall metabolic health

ADA In 2022, the Standards of Medical Care in Diabetes published by the ADA recommended the concurrent use of GLP-1 RAs in patients with ASCVD and T2DM, independent of HbA1c and metformin use [52]

Book your IV therapy at a location near you and start feeling your best today